Study reports validation of the first point-of-care genetic test in medicine, regarding use of antiplatelet therapy
A study published Online First by the Lancet reports the successful validation and clinical application of the first point-of-care genetic test in medicine. The test successfully identifies the CYP2C19*2 allele: a common genetic variant associated with increased rates of major adverse events in individuals given clopidogrel after percutaneous coronary intervention (PCI), thus avoiding complications in those patients. The Article is by Dr Derek Y F So, University of Ottawa Heart Institute, Ottawa, Canada, and colleagues.
Treatment with aspirin and clopidogrel is standard care for patients after PCI, in order to reduce the risk of blot clots. However, many patients given this dual antiplatelet regimen remain vulnerable to major adverse cardiovascular events. This persistent vulnerability is associated with high on-treatment platelet reactivity (that can lead to sudden blockage within stents causing heart attacks or death), which is characterised by inadequate inhibition of the platelet P2Y12 receptor after treatment with clopidogrel. Although several clinical variables have been implicated, the strongest predictor is the loss-of-function CYP2C19*2 allele (rs4244285). This common genetic variant is carried by nearly 30% of individuals of western European ancestry and as many as 50% of those of Asian descent.
Prasugrel and ticagrelor are novel P2Y12 inhibitors that provide more potent platelet inhibition than does clopidogrel. Both agents reduce major adverse cardiovascular events after acute coronary syndrome; however, they are also associated with increased bleeding complications.
Notably, retrospective genetic studies showed that prasugrel and ticagrelor were unaffected by the CYP2C19*2 allele. Prospective identification of CYP2C19*2 carrier status might allow personalisation of dual antiplatelet treatment after PCI that successfully minimises major adverse cardiovascular events and adverse bleeding events.
A point-of-care genetic test for the CYP2C19*2 allele with a buccal swab has been developed (Spartan RX CYP2C19, Spartan Biosciences, Ottawa, ON, Canada). This bedside technology enables health-care personnel with no previous training in genetic laboratory techniques to undertake genotyping. Thus the authors aimed to assess the clinical feasibility and pharmacodynamic efficacy of personalised dual antiplatelet treatment in patients receiving PCI for treatment of acute coronary syndrome and stable coronary artery disease. Usual care generally consists of treating all patients with the same medical regimen (most often aspirin and clopidogrel) whereas this new genetic test enables physicians to personalise therapy and selectively administer a more potent anti-platelet agent (such as prasugrel) to those at high risk of treatment failure with clopidogrel.
200 patients were enrolled into our prospective, randomised, proof-of-concept study. Patients undergoing PCI for acute coronary syndrome or stable angina were randomly assigned to rapid point-of-care genotyping or to standard treatment. Individuals in the rapid genotyping group were screened for the CYP2C19*2 allele. Carriers were given 10 mg prasugrel daily, and non-carriers and patients in the standard treatment group were given 75 mg clopidogrel daily. The primary endpoint was the proportion of CYP2C19*2 carriers with high on-treatment platelet reactivity (P2Y12 reactivity unit [PRU] value of more than 234) after 1 week of dual antiplatelet treatment, which is a marker associated with increased adverse cardiovascular events.
After randomisation, 187 patients completed follow-up (91 rapid genotyping group, 96 standard treatment). 23 individuals in each group carried at least one CYP2C19*2 allele. None of the 23 carriers in the rapid genotyping group had a PRU value of more than 234 at day 7, compared with seven (30%) given standard treatment. The point-of-care genetic test had a sensitivity of 100% and a specificity of 99%.
The authors conclude: "As far as we are aware, our study is the first to validate and to show clinical use of point-of-care genetic testing. It is the first randomised investigation of selective use of prasugrel in CYP2C19*2 carriers after PCI. Our findings suggest that personalisation of antiplatelet therapy might reduce adverse ischaemic outcomes; use of prasugrel only in high-risk individuals might also minimise adverse bleeding events. The development of practical point-of-care genetic testing in our study will help to integrate genetics into the clinical setting and will allow large-scale investigations to definitively assess the value of pharmacogenetic strategies."
Dr So adds*: "For the first time in clinical medicine, we have proven that a simple bedside test can enable rapid genetic testing and subsequent personalised therapy. This is an important step towards integrating pharmacogenomic strategies into clinical care."
In a linked Comment, Dr Amber L Beitelshees, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA, says: "The RAPID GENE study provides much-needed impetus by showing that genotyping can be done in a timely manner and incorporated into the clinical workflow as we wait for the results of large outcome-driven randomised trials."
More information: Study online: www.thelancet.com/… 1-5/abstract
Provided by Lancet
- Increasing dosage of clopidogrel for patients with genetic variation improves response to medication Nov 16, 2011 | not rated yet | 0
- Genetic variations linked with worse outcomes with use of antiplatelet drug for cardiac procedures Oct 26, 2010 | not rated yet | 0
- Results of the TRIGGER-PCI trial reported at TCT 2011 Nov 09, 2011 | not rated yet | 0
- World's first bedside genetic test proves effective Nov 09, 2011 | not rated yet | 0
- Genetic variation associated with poorer response, cardiovascular outcomes with use of clopidogrel Aug 25, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
The idea behind a reverse shock
5 hours ago So in a supernova explosion for example (5th slide) http://www.astro.princeton.edu/~burrows/classes/541/blastwavesChisari.pdf Ambient medium is...
Guass's Law for a charge distribution
5 hours ago First, this is not a homework question, just something I've been confused about for some time. I understand how to use Guass's law in many ways but...
6 hours ago Hello :) i'm new to this forum, so excuse me for my straightforwardness ;) I'm working on my bachelor work and i can't find a solution. I'm writing...
siphon and bernouli theorum
7 hours ago 1. I found this diagram on book but there weren't any description.can someone tell me, what its trying to tell specially by those two red lines...
Hot gas expansion rate into outer space
7 hours ago Good Morning Sirs, it seems to be surprisingly hard to get the numbers of a mystery: How fast expand hot rocket exhaust gases into empty space? ...
Magnetic field lines through copper
13 hours ago Hello. Assume an electron gun, as in CRT, made of plumbing copper instead of glass. Using magnetic scanning coils to move electron beam. Will the...
- More from Physics Forums - Classical Physics
More news stories
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
Cardiology 10 hours ago | not rated yet | 1
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
Cardiology 10 hours ago | not rated yet | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
Cardiology 11 hours ago | 5 / 5 (2) | 5
Transcatheter aortic valve implantation (TAVI) is effective and safe in Asian patients, according to early experience based on first results from a multicentre Asian registry reported at EuroPCR 2013.
Cardiology May 24, 2013 | not rated yet | 0
Routinely measuring fractional flow reserve (FFR) using pressure wire assessment during coronary angiography for diagnosis of chest pain leads to significant changes in the management of one in four patients, according to ...
Cardiology May 24, 2013 | not rated yet | 0
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
2 hours ago | not rated yet | 0
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
10 hours ago | not rated yet | 0
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
May 20, 2013 | 4.8 / 5 (30) | 9 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
May 22, 2013 | 5 / 5 (4) | 6 |
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
May 24, 2013 | 4 / 5 (4) | 4 |
Salamanders' immune systems are key to their remarkable ability to regrow limbs, and could also underpin their ability to regenerate spinal cords, brain tissue and even parts of their hearts, scientists have ...
May 20, 2013 | 4.9 / 5 (7) | 5 |